Renal Cell Carcinoma Clinical Trial
— SRWECOfficial title:
Study of the Effectiveness and Safety of Cabozantinib Treatment in Patients With Advanced Renal Cell Carcinoma (RCC) Under a Spanish Managed Access Program and Real-world Practice
Verified date | October 2022 |
Source | Spanish Oncology Genito-Urinary Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
RCC (Renal Cell Carcinoma) is the most common form of kidney cancer, accounting for 2-3% of all adult malignancies and for 90% of all kidney cancers. The incidence of RCC has steadily increased over the past two decades, showing a plateau in recent years. Many patients with RCC remain asymptomatic until late disease stages and other patients have disease at diagnosis (metastatic RCC or mRCC). Recently, the tyrosine kinase inhibitor (TKI) cabozantinib was approved as a first-line therapy for patients with advanced clear-cell RCC (ccRCC). Cabozantinib was initially approved for patients previously treated with antiangiogenic therapy based on the phase 3 METEOR study, which demonstrated a clinical benefit compared with everolimus. Immunotherapy has been also developed in ccRCC. The frontline treatment paradigm for ccRCC has evolved, particularly for intermediate-/poor-risk patients, with the recent addition of cabozantinib and nivolumab/ipilimumab (immunotherapy), but overall survival data are needed to understand their benefit-to-risk profiles compared with established therapies. In October 2016, the Spanish Agency of medicines (AEMPS) granted the temporary Authorization for special use to Cabometyx® 20/40/60 mg within a Managed Access Program (MAP) for the treatment of advanced RCC in adults following prior VEGF-targeted therapy (Vascular Endothelial Growth Factor targeted therapy). The MAP allows the possibility of using a medicinal product which is not yet commercially available or approved. By the end of the MAP period, on July 2017, 136 patients had been included by 61 centers who received at least one dose of Cabometyx® for the treatment of advanced RCC. Since then, Cabometyx® 20/40/60 mg was made commercially available for the treatment of advanced RCC in adults following prior VEGF-targeted therapy. After the commercialization of Cabometyx® in July 2017 in Spain, the inclusion of new patients in the MAP was closed but those patients that were already included continued receiving Cabometyx® free of charge until clinical decision. In July 2018, the European Commission approved a new indication for adult patients previously untreated with intermediate or poor risk. Based on this rationale, the aim of this study is to obtain safety and effectiveness information regarding the use of cabozantinib in a non-selected RCC population, both in patients that received this agent under the MAP or under routine clinical prescription (real-world [RW]).
Status | Completed |
Enrollment | 275 |
Est. completion date | June 30, 2022 |
Est. primary completion date | June 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Male or females, aged 18 years or older. 2. Diagnosis of advanced Renal Cell Carcinoma (RCC) 3. Alive or dead patients at study initiation who received at least one dose of cabozantinib for the treatment of RCC between October 2016 and 1 st June 2019. 4. Alive patients who agree to participate and signed the Informed Consent Form (ICF). Exclusion Criteria: 1. Patients who decline consent. 2. Patients whose hospital medical records are unavailable for review. |
Country | Name | City | State |
---|---|---|---|
Spain | Centro Oncológico de Galicia | A Coruña | Galicia |
Spain | Hospital Universitario de Badajoz | Badajoz | Extremadura |
Spain | Hospital Clínic de Barcelona | Barcelona | |
Spain | Hospital de la Santa Creu i Sant Pau | Barcelona | Catalonia |
Spain | Hospital Del Mar | Barcelona | |
Spain | Hospital Universitari Vall D'Hebron | Barcelona | |
Spain | Hospital Universitario de Burgos | Burgos | |
Spain | Hospital San Pedro de Alcántara | Cáceres | |
Spain | Hospital Provincial de Castellón | Castellón De La Plana | |
Spain | Hospital General de Ciudad Real | Ciudad Real | |
Spain | Hospital Universitario Reina Sofía | Córdoba | Andalucía |
Spain | Complejo Hospitalario Universitario de Ferrol | Ferrol | Galicia |
Spain | Hospital Universitario Juan Ramón Jiménez | Huelva | Andalucía |
Spain | Complejo Hospitalario de Jaén | Jaén | Andalucía |
Spain | Hospital Unviersitario de Gran Canaria Doctor Negrin | Las Palmas De Gran Canaria | Islas Canarias |
Spain | Hospital Universitario de León | León | Castilla Y León |
Spain | Hospital Universitario Lucus Augusti | Lugo | |
Spain | Complejo Hospitalario Universitario Ourense | Ourense | Galicia |
Spain | Hospital Universitario Central de Asturias | Oviedo | Asturias |
Spain | Hospital Son Llatzer | Palma De Mallorca | Islas Baleares |
Spain | Hospital Universitari Son Espases | Palma De Mallorca | Illes Ballears |
Spain | Hospital Universitari Sant Joan de Reus | Reus | Catalunya |
Spain | Consorci Corporació Sanitària Parc Taulí de Sabadell | Sabadell | Catalunya |
Spain | Hospital Universitari Parc Taulí | Sabadell | Barcelona |
Spain | Hospital Universitario Nuestra Señora de Candelaria | Santa Cruz De Tenerife | Islas Canarias |
Spain | Hospital Virgen de La Salud | Toledo | |
Spain | Fundación Instituto Valenciano de Oncología | Valencia | |
Spain | Hospital Arnau de Vilanova | Valencia | |
Spain | Hospital Clínico Universitario de Valenica | Valencia | Comunitat Valenciana |
Spain | Hospital Universitari Dr. Peset | Valencia | Comunitat Valenciana |
Spain | Hospital Universitari i Politècnic La Fe | Valencia | Comunidad Valenciana |
Spain | Hospital Universitario Alvaro Cunqueiro | Vigo |
Lead Sponsor | Collaborator |
---|---|
Spanish Oncology Genito-Urinary Group | Ipsen, Syntax for Science, S.L |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effectiveness: Progression-Free Survival | Evaluation of the effectiveness of cabozantinib in terms of investigator-assessed PFS (Progression-Free Survival) based on the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 | Through study completion, an average of 2 years | |
Primary | Incidence of Adverse Reactions | Evaluation of the safety of cabozantinib by recording the incidence of adverse reactions in both MAP and RW cohorts. | Through study completion, an average of 2 years | |
Primary | Incidence of dose reductions | Evaluation of the safety of cabozantinib by recording the incidence of dose reductions in both MAP and RW cohorts. | Through study completion, an average of 2 years | |
Primary | Incidence of temporary interruptions or discontinuations | Evaluation of the safety of cabozantinib by recording the Incidence of temporary interruptions or discontinuations in both MAP and RW cohorts. | Through study completion, an average of 2 years | |
Primary | Incidence of use of medications to manage adverse reactions | Evaluation of the safety of cabozantinib by recording the incidence of use of medications to manage adverse reactions in both MAP and RW cohorts. | Through study completion, an average of 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04987203 -
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
|
Phase 3 | |
Recruiting |
NCT06391879 -
Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Recruiting |
NCT04623502 -
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
|
N/A | |
Completed |
NCT02853344 -
Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
|
Phase 2 | |
Terminated |
NCT04088500 -
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT05070637 -
Circulating Tumor Cell Reducing No-touch Nephrectomy
|
N/A | |
Active, not recruiting |
NCT03634540 -
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
|
Phase 2 | |
Not yet recruiting |
NCT06049030 -
A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01358721 -
Phase I Biomarker Study (BMS-936558)
|
Phase 1 | |
Active, not recruiting |
NCT04503148 -
Anesthesia and Cancer Study: Renal Cell Carcinoma
|
N/A | |
Completed |
NCT02386826 -
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
|
Phase 1 | |
Not yet recruiting |
NCT05808608 -
A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03323710 -
Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT02787915 -
DC1s-CTL Cellular Therapy for Renal Cell Carcinoma
|
Phase 1/Phase 2 |